(IN BRIEF) A new spin-out drug discovery company from the University of Liverpool called Sulantrix is exploring new cancer medicines targeting previously untapped classes of pseudoenzymes. The company is led by Professor Patrick Eyers and CEO David Williams, who has … Read the full press release
Posted in Education, Healthcare, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AI, Cancer, David Williams, Dr Emma Fairweather, drug discovery, Emma Nolan, Enterprise Investment Funding, ISMIB, Multi-omics Platforms, Professor Anthony Hollander, Professor Patrick Eyers, pseudoenzymes, spin-out, Sulantrix, University of Liverpool
The challenge aims at helping the discovery of transformative breakthroughs across AstraZeneca’s core disease areas Successful proposals will secure fully funded postdoctoral research positions (PRESS RELEASE) CAMBRIDGE, 17-Mar-2022 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), a British-Swedish multinational pharmaceutical and biotechnology … Read the full press release
Scientists at the University of Bristol have developed new virtual reality (VR) cloud-based tools to help academics and industry progress new drugs, materials and boost the teaching of chemistry. BRISTOL, 03-Jul-2018 — /EuropaWire/ — A joint team of computer science and … Read the full press release
Posted in Education, Internet & Online, Science, Technology, United Kingdom
Tagged Adrian Mulholland, cloud infrastructure, cloud-based tools, Dr David Glowacki, drug discovery, Interactive Scientific, Michael O’Connor, nanotech, Oracle Corporation, RESEARCH, simulations, start-up, University of Bristol, virtual reality technology, VR
Marrongelli selected for her expertise in Botanical Drug Development LONDON, 15-Jun-2018 — /EuropaWire/ — As a leading expert in her field, Dr. Christina Marrongelli, PharmD has been chosen by the World Congress on Pharmacology & Chemistry of Natural Compounds to … Read the full press release
Posted in France, Government, Healthcare, News, Pharma & Biotech, Science, United Kingdom
Tagged biomedical sciences, Botanical Drug Development, botanical drugs, botanical medicines, botanicals, crofelemer, Dr. Christina Marrongelli, drug development, drug discovery, FD&C Act, herbal drug market, herbal medicines, heterogeneous botanical drug products, Maryland Board of Physicians, Medical University of South Carolina, medicine, Mytesi, natural compounds, Naturopathic Doctors Formulary Council, pharmaceutical market, pharmaceutical marketing, pharmacognosy, Pharmacology, PharmD, research and development, sinecatechins, The pharmaceutical industry, United States, Veregen®, World Congress on Pharmacology & Chemistry of Natural Compounds
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
